Arcutis Biotherapeutics, Inc.
ARQT
$20.69
-$0.55-2.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.38M | -16.14M | -44.32M | -93.27M | -129.72M |
| Total Depreciation and Amortization | 2.10M | 4.51M | 4.26M | 4.97M | 4.58M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.63M | 40.83M | 41.57M | 40.74M | 41.53M |
| Change in Net Operating Assets | -15.35M | -34.83M | -34.07M | -17.93M | -27.33M |
| Cash from Operations | 26.99M | -5.63M | -32.56M | -65.49M | -110.94M |
| Capital Expenditure | -78.00K | -686.00K | -686.00K | -829.00K | -751.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -53.26M | -29.57M | 39.49M | 149.66M | 70.02M |
| Cash from Investing | -53.34M | -30.25M | 38.80M | 148.83M | 69.27M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -100.00M | -100.00M | -100.00M |
| Issuance of Common Stock | 7.65M | 6.97M | 5.84M | 4.76M | 4.83M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7.65M | 6.97M | -94.16M | -95.24M | -95.17M |
| Foreign Exchange rate Adjustments | 45.00K | 168.00K | -125.00K | 68.00K | -158.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.65M | -28.74M | -88.04M | -11.84M | -136.99M |